December CVU tickets are now available for purchase
Tickets are now available for our first virtual Clinical Vaccinology Update (CVU). This will be an all-day event held on December 7 2020.
We are excited to welcome both local and international presenters covering a wide range of immunisation topics.
To view a draft program of the day's events, and for ticketing information, please follow the link below:
Clinical Vaccinology Update: December 7 2020
Who pays compensation if a COVID-19 vaccine has rare side-effects? Here's the little we know about Australia's new deal
In the recent federal budget, the Australian Government revealed it would provide indemnity against liability for both the AstraZeneca Oxford and the University of Queensland COVID-19 vaccine candidates. Should either vaccine be approved, and if rare side-effects occur, the government will be responsible for providing compensation. Vaccine compensation schemes currently exist in many countries however, at present Australia is not one of them.
The following article, published in The Conversation, outlines what is known about the proposed indemnity deal and what it means for Australians.
要阅读全文，请点击以下链接：
New immunisation reference page: The Royal Children's Hospital COVID-19 follow-up clinic
Our new reference page provides details on the COVID-19 follow-up clinic at The Royal Children's Hospital, which aims to provide support, acute care and long-term follow-up to COVID-19 positive children and their families. For further information, including how to refer children to the service, please follow the link below:
MVEC: The Royal Children's Hospital COVID-19 follow-up clinic
The New York Times: She hunts viral rumors about real viruses
In the following article by the New York Times, Anthropologist and Director of the Vaccine Confidence Project, Professor Heidi Larson, suggests that vaccine hesitancy is not a byproduct of misinformation, but represents a problem with trust. Heidi's research focuses on what factors undermine vaccine acceptance and immunisation uptake across the globe. She suggests that in order to build trust, health care providers need to focus communication strategies on answering the questions being asked and not just providing scientific information and public health recommendations.
Read the article in full below:
The New York Times: She hunts viral rumors about real viruses
Heidi was recently a special guest on our COVID-19 Road to a vaccine podcast series. To listen to Heidi's episode follow the below link to our podcast page:
Australian Technical Advisory Group on Immunisation (ATAGI) COVID-19 Working Group
The role of the 澳大利亚免疫技术咨询小组 (ATAGI) is to provide independent advice to the Minister for Health on all matters relating to immunisation in Australia. In September 2020 ATAGI convened a new SARS-CoV-2 (COVID-19) working group. The key objectives of this group are to provide advice on COVID-19 immunisation programs and policies, to improve confidence in COVID-19 vaccines and to ensure equitable access to COVID-19 vaccines as they become available in Australia.
To learn more, please see below:
澳大利亚政府卫生部：澳大利亚免疫技术咨询小组 (ATAGI) COVID-19 工作组
Save the date for our first virtual Clinical Vaccinology Update!
MVEC is excited to announce that our first virtual Clinical Vaccinology Update (CVU) will be held on December 7, 2020.
Program details and ticketing information will be announced shortly.
EMA starts first rolling review of a COVID-19 vaccine in the EU
The European Medicines Agency (EMA) has begun a "rolling review" of the AstraZeneca Oxford SARS-CoV-2 vaccine candidate. Normal regulatory processes for medicines involve the submission of all safety and efficacy data to the Agency at the completion of clinical trials. A "rolling review" means that the Agency can begin evaluating data as it becomes available. By employing this method of approval, the regulation process will maintain its usual quality and safety standards, but be shorter than the usual process due to the time gained by reviewing data as it becomes available.
To learn more please read below:
EMA starts first rolling review of a COVID-19 vaccine in the EU
Frontiers in Immunology: Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines
With over 200 COVID-19 vaccine candidates currently in pre-clinical and clinical trials, the following article reviews what we know about the immune response to SARS-CoV-2 infection and explores the various vaccine platforms being utilised to develop a safe and effective vaccine. Potential issues including adverse effects and the need for mass production are also discussed, as well as the challenges of rapid and equitable vaccine delivery.
Read the article in full here:
新冠疫苗之路第15集：林恩·吉拉姆教授
在第 15 集中，我们的主持人 Nigel Crawford 副教授与 Lynn Gillam 教授进行了对话。林恩是一位接受过哲学和生物伦理学培训的临床伦理学家。她是墨尔本大学墨尔本人口与全球健康学院健康公平中心的教授；澳大利亚墨尔本皇家儿童医院儿童生物伦理中心学术主任。儿童生物伦理中心为临床医生提供有关患者护理问题的道德决策等支持。 Nigel 和 Lynn 将利用美国堪萨斯城儿童慈善医院的 John Lantos 博士在最近举行的生物伦理学电子会议上提出的观点框架，讨论 SARS-CoV-2 疫苗中提出的一些伦理问题儿童生命伦理中心主办：
- 认识到不做某事或不进行研究本身就是一个决定的重要性
- “太快不安全”的概念——有些步骤需要花他们一直采取的时间，有些事情可以更快地完成，认识到如果你什么都不做，你就会允许伤害发生
- 伦理委员会的作用和疫苗的开发方式，即在研究中使用更年轻、更健康的参与者，而不是患有最严重疾病的个人
- 儿童和老年人参与临床试验以及其伦理考虑的主要差异
- 当 SARS-CoV-2 疫苗上市时，全球公平获取疫苗的机会是什么？谁首先获得这些疫苗？应该如何做出这些决定？
- 公民陪审团在决定谁在大流行情况下优先获得疫苗方面的作用
- 强制接种疫苗
- 胎儿胚胎细胞系在疫苗开发中的应用
链接
- 澳洲金融评论：疫苗让人类面临下一次道德考验
- MVEC：用于疫苗开发平台的胎儿胚胎细胞
- 墨尔本大学：澄清可能的 COVID-19 疫苗的伦理问题
- BMC 公共卫生：让公众参与大流行病规划：一种深思熟虑的方法
- 社会科学与医学：公民陪审团在卫生政策决策中的运用：系统评价
- RCH Grand Rounds：不让大流行白白浪费——新冠危机如何带来更好的医疗保健服务
在这里收听该片段：
喇叭 - 苹果 - Spotify 音乐
NEJM: Evaluating and Deploying Covid-19 Vaccines — The Importance of Transparency, Scientific Integrity, and Public Trust
The following article published in the New England Journal of Medicine, discusses the importance of adhering to well-established and transparent regulatory processes when it comes to approving a COVID-19 vaccine. Reassuring the public with robust scientific evaluation from independent bodies, without interference from governments for the purposes of political advantage, is essential to promote public confidence and ensure the success of vaccination programs.
Read the article in full here: